BMC Cancer

1. CHU Z, Yang S, Li Q, Shang J, et al
   The V protein in oncolytic Newcastle disease virus promotes HepG2 hepatoma cell proliferation at the single-cell level.
   BMC Cancer. 2023;23:346.
   

   >> Share

   
   
2. GAO X, Jiang P, Wei X, Zhang W, et al
   Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.
   BMC Cancer. 2023;23:359.
   

   >> Share

   
   

   
   BMC Gastroenterol

3. SUMIYOSHI S, Kiuchi J, Kuriu Y, Arita T, et al
   Postoperative liver dysfunction is associated with poor long-term outcomes in patients with colorectal cancer: a retrospective cohort study.
   BMC Gastroenterol. 2023;23:128.
   

   >> Share

   
   
4. YANG L, Wang YR, Mou ZQ, Xiong PF, et al
   A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification.
   BMC Gastroenterol. 2023;23:131.
   

   >> Share

   
   

   
   Cancer Res

5. WOOD CS, Pennel KAF, Leslie H, Legrini A, et al
   Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases.
   Cancer Res. 2023;83:1329-1344.
   

   >> Share

   
   
6. FANG JH, Chen JY, Zheng JL, Zeng HX, et al
   Fructose Metabolism in Tumor Endothelial Cells Promotes Angiogenesis by Activating AMPK Signaling and Mitochondrial Respiration.
   Cancer Res. 2023;83:1249-1263.
   

   >> Share

   
   

   
   Dig Dis Sci

7. MAHMUD N, Reddy KR, Taddei TH, Kaplan DE, et al
   Type of Infection Is Associated with Prognosis in Acute-on-Chronic Liver Failure: A National Veterans Health Administration Study.
   Dig Dis Sci. 2023;68:1632-1640.
   

   >> Share

   
   
8. UNALP-ARIDA A, Ruhl CE
   Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States.
   Dig Dis Sci. 2023;68:1237-1252.
   

   >> Share

   
   
9. KHAKOO NS, Sultan S, Reynolds JM, Levy C, et al
   Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
   Dig Dis Sci. 2022 Sep 30. pii: 10.1007/s10620-022-07704.
   

   >> Share

   
   
10. JAMMA T
    SALL4 Expression in Epithelial Gastric Cancer: Epigenetic or Epiphenomenon?
    Dig Dis Sci. 2023 Mar 6. doi: 10.1007/s10620-022-07791.
    

    >> Share

    
    
11. PATERNOSTRO R
    Muscle Mass Effect: The Importance of Diagnosing and Treating Sarcopenia in Patients with Advanced Chronic Liver Disease.
    Dig Dis Sci. 2023;68:1089-1090.
    

    >> Share

    
    

    
    Eur Radiol

12. SAID D, Carbonell G, Stocker D, Hectors S, et al
    Semiautomated segmentation of hepatocellular carcinoma tumors with MRI using convolutional neural networks.
    Eur Radiol. 2023 Apr 18. doi: 10.1007/s00330-023-09613.
    

    >> Share

    
    

    
    Gastrointest Endosc

13. NAGA M, Naga YM
    Duodenal varices injection therapy.
    Gastrointest Endosc. 2023;97:997-998.
    

    >> Share

    
    
14. HASHIMOTO Y, Miyagaki A
    Peroral cholangioscopic findings of acute ischemic cholangiopathy caused by transarterial chemoembolization.
    Gastrointest Endosc. 2023 Jan 13:S0016-5107(23)00021.
    

    >> Share

    
    

    
    Hepatology

15. TAPPER EB, Ospina E, Salim N, Chen X, et al
    Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient reported outcomes - the Mi-Kristal RCT.
    Hepatology. 2023 Apr 18. doi: 10.1097/HEP.0000000000000408.
    

    >> Share

    
    
16. MALHI H, Shah V, Gores GJ
    Thematic reviews: the future of hepatology.
    Hepatology. 2023 Apr 19. doi: 10.1097/HEP.0000000000000409.
    

    >> Share

    
    
17. UFERE NN
    Home is where the liver is?: moving beyond readmissions to time at home as a patient-centered and pragmatic quality measure in cirrhosis care.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000415.
    

    >> Share

    
    
18. MATHUR M, Yeh YT, Arya RK, Jiang L, et al
    Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:1688-1701.
    

    >> Share

    
    
19. JUAREZ-FERNANDEZ M, Goikoetxea-Usandizaga N, Porras D, Garcia-Mediavilla MV, et al
    Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
    Hepatology. 2023;77:1654-1669.
    

    >> Share

    
    
20. ZABRANSKY DJ, Danilova L, Leatherman JM, Lopez-Vidal TY, et al
    Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
    Hepatology. 2023;77:1566-1579.
    

    >> Share

    
    
21. LUO W, Wang Y, Li Y, Zhang T, et al
    Letter to the editor: Adipose lipolysis is important for ethanol to induce fatty liver in the NIAAA murine model of chronic and binge ethanol feeding.
    Hepatology. 2023;77:E88-E89.
    

    >> Share

    
    
22. ZHANG S, Wan D, Zhu M, Wang G, et al
    CD11b + CD43 hi Ly6C lo splenocyte-derived macrophages exacerbate liver fibrosis via spleen-liver axis.
    Hepatology. 2023;77:1612-1629.
    

    >> Share

    
    
23. WEN Y, Emontzpohl C, Xu L, Atkins CL, et al
    Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis.
    Hepatology. 2023;77:1580-1592.
    

    >> Share

    
    
24. CUCCHETTI A, Casadei-Gardini A
    Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised.
    Hepatology. 2023;77:1463-1464.
    

    >> Share

    
    
25. BERARDI G, Ratti F, Sposito C, Nebbia M, et al
    Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
    Hepatology. 2023;77:1527-1539.
    

    >> Share

    
    
26. ARTRU F, Rautou PE, Denys A
    Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO).
    Hepatology. 2023;77:E91-E92.
    

    >> Share

    
    
27. GU W, Queck A, Trebicka J, Praktiknjo M, et al
    Reply: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis.
    Hepatology. 2023;77:E101.
    

    >> Share

    
    
28. KNIGHT GM, Thornburg B, Salem R
    Reply: Discussing the place of TIPS in non-cirrhotic patients with chronic extra hepatic portal vein occlusion refractory to standard of care therapy.
    Hepatology. 2023;77:E93-E94.
    

    >> Share

    
    
29. RINELLA ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, et al
    AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
    Hepatology. 2023;77:1797-1835.
    

    >> Share

    
    
30. EBRAHIMI F, Ludvigsson JF
    Letter to the editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2023;77:E107-E108.
    

    >> Share

    
    
31. SANGHA K, Chang ST, Cheung R, Deshpande VS, et al
    Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Hepatology. 2023;77:1702-1711.
    

    >> Share

    
    

    
    Indian J Gastroenterol

32. MALAKAR S, Mathur A, Elhence A, Ghoshal UC, et al
    Hepatogastric fistula: A rare complication of liver abscess.
    Indian J Gastroenterol. 2023 Apr 18. doi: 10.1007/s12664-023-01347.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

33. CHO SH, Song TJ, Park JS, Yoon JH, et al
    Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
    J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
    

    >> Share

    
    
34. ALABBAS SY, Giri R, Oancea I, Davies J, et al
    Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver.
    J Gastroenterol Hepatol. 2023;38:609-618.
    

    >> Share

    
    

    
    J Hepatol

35. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
    Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
    J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
    

    >> Share

    
    
36. DALY AK, Bjornsson ES, Lucena MI, Andrade RJ, et al
    Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
    J Hepatol. 2023;78:e165-e166.
    

    >> Share

    
    
37. ZHANG H, Peng Y, Tang X
    Comment on: Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.
    J Hepatol. 2023;78:e177-e178.
    

    >> Share

    
    
38. BINET Q, Hermans MP, Lanthier N
    Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues.
    J Hepatol. 2023;78:e166-e167.
    

    >> Share

    
    
39. RATZIU V, Charlton M
    Rational combination therapy for NASH: Insights from clinical trials and error.
    J Hepatol. 2023;78:1073-1079.
    

    >> Share

    
    
40. SURIAL B, Ramirez Mena A, Roumet M, Limacher A, et al
    External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
    J Hepatol. 2023;78:947-957.
    

    >> Share

    
    
41. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
    Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
    J Hepatol. 2023;78:989-997.
    

    >> Share

    
    
42. FALKEVALL A, Mehlem A, Folestad E, Ning FC, et al
    Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    J Hepatol. 2023;78:901-913.
    

    >> Share

    
    
43. AJMERA V, Loomba R
    Reply to: "Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues".
    J Hepatol. 2023;78:e168-e169.
    

    >> Share

    
    
44. ZHANG CJ, Meyer SR, O'Meara MJ, Huang S, et al
    A human liver organoid screening platform for DILI risk prediction.
    J Hepatol. 2023;78:998-1006.
    

    >> Share

    
    
45. LEE E, Korf H, Vidal-Puig A
    An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.
    J Hepatol. 2023;78:1048-1062.
    

    >> Share

    
    
46. HARRISON SA, Thang C, Bolze S, Dewitt S, et al
    Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    J Hepatol. 2023;78:914-925.
    

    >> Share

    
    
47. DI MARTINO V
    Methotrexate-induced liver fibrosis: The end of a long-held belief.
    J Hepatol. 2023;78:896-897.
    

    >> Share

    
    
48. FUNDORA Y, Fuster-Anglada C, Bassaganyas C, Toapanta D, et al
    An infrequent cause of spontaneous liver rupture.
    J Hepatol. 2023;78:e160-e161.
    

    >> Share

    
    
49. YIN JL, Ala A, Miquel R
    Histology - further raising the diagnostic bar in chronic liver disease.
    J Hepatol. 2023;78:e162-e164.
    

    >> Share

    
    

    
    Nat Rev Cancer

50. SIMON SM
    Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma.
    Nat Rev Cancer. 2023 Apr 20. doi: 10.1038/s41568-023-00575.
    

    >> Share

    
    

    
    PLoS One

51. CUSHMAN M, Callas PW, Alexander KS, Wadley V, et al
    Nonalcoholic fatty liver disease and cognitive impairment: A prospective cohort study.
    PLoS One. 2023;18:e0282633.
    

    >> Share

    
    
52. WANG L, Peng Y, Qin S, Wan X, et al
    First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    PLoS One. 2023;18:e0279786.
    

    >> Share

    
    
53. SOHAIL J, Zubair M, Hussain K, Faisal M, et al
    Pharmacological activities of Artemisia absinthium and control of hepatic cancer by expression regulation of TGFbeta1 and MYC genes.
    PLoS One. 2023;18:e0284244.
    

    >> Share

    
    

    
    Transplant Proc

54. AKBULUT S, Tamer M, Saritas S, Unal O, et al
    Immunosuppressive Medication Adherence in Patients With Hepatocellular Cancer Who Have Undergo Liver Transplantation: A Case Control Study.
    Transplant Proc. 2023 Apr 18:S0041-1345(23)00164.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share